Ads
related to: Opdivo- Clinical Trial Results
Review Data From
3 Clinical Studies
- Dosing & Administration
Get Recommended
Dosing
- Peer Videos
Watch Videos Sharing
Clinical And Patient Experiences
- Request A Rep
Contact A Representative To
Learn More About This Product
- Mechanism Of Action
Details About Therapy
MOA
- Safety Information
Review Key Safety
Information
- Clinical Trial Results
Search results
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
InvestorPlace· 18 hours agoWith the market trading near all-time highs, undervalued healthcare stocks offer a compelling...
Schechter Investment Advisors LLC Sells 11,351 Shares of Bristol-Myers Squibb (NYSE:BMY)
ETF DAILY NEWS· 5 hours agoSchechter Investment Advisors LLC reduced its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 42.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor ...
20 Countries with the Highest Heart Disease Deaths Per Capita
Insider Monkey via Yahoo Finance· 2 days agoIn this article, we will be taking a look at the 20 countries with the highest disease deaths per...
Council Post: What's Driving Big Pharma's Recent Market Performance?
Forbes· 3 days agoThe financial performance of major pharmaceutical companies highlights the divergent trajectories of...
Scancell Holdings doses first patient with iSCIB1+
Proactive Investors· 2 days agoScancell Holdings PC, a developer of immunotherapies for cancer and infectious diseases, has reached a pivotal milestone in its clinical development with...
Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer -...
Benzinga· 7 days agoWednesday, the European Commission approved Bristol Myers Squibb & Co’s BMY Abecma (idecabtagene...
Blackston Financial Advisory Group LLC Makes New $219,000 Investment in Bristol-Myers Squibb...
ETF DAILY NEWS· 6 hours agoBlackston Financial Advisory Group LLC purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities ...
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
Benzinga· 1 day agoVidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619;
Ads
related to: Opdivo